# Emicizumab PUPs and Nuwiq ITI Study

> **NCT04030052** · PHASE3 · WITHDRAWN · sponsor: **Emory University**

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Nuwiq (low dose protocol)
- **DRUG:** HEMLIBRA
- **DRUG:** Nuwiq (Atlanta protocol)

## Key facts

- **NCT ID:** NCT04030052
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-02-17
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-01-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The Emi PUPs and Nuwiq ITI study has been closed due to slow enrollment and study site startup.
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04030052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04030052, "Emicizumab PUPs and Nuwiq ITI Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04030052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*